Back to top

Analyst Blog

On Nov 1, we reiterated our Neutral recommendation on lab chemical and life sciences company Sigma-Aldrich Corporation (SIAL - Analyst Report). While the company should gain from acquisitions and expansion initiatives, we continue to tread with caution considering currency headwind and persistent challenges in its research business.
Why Kept?
Sigma-Aldrich’s third-quarter 2013 revenues and adjusted earnings, reported on Oct 22, beat the Zacks Consensus Estimate. The company saw organic sales gain across all business units in the quarter. While Sigma-Aldrich backed its sales growth outlook for 2013, it raised the bottom end of its earnings guidance citing tax benefits.
Sigma-Aldrich’s significant investments in sales, marketing and R&D initiatives are generating demand for its products. The company is seeking to take advantage of country-specific opportunities by expanding its presence in high-growth emerging markets. It is actively expanding its foothold in the Asia-Pacific region, especially in the fast-growing emerging markets of India and China.
The BioReliance acquisition, which extended Sigma-Aldrich’s reach into the promising new market of biologic drugs, should add to its growth in 2013. The company also remains committed to offering returns to its shareholders through cash dividends and share repurchases. Sigma-Aldrich has returned $193 million to its shareholders in the first nine months of 2013 in the form of dividends and share repurchases.
However, Sigma-Aldrich’s research business, especially with large pharmaceutical companies, is expected to continue to face challenges due to weak academic spending in the U.S. and Europe. National Institutes of Health (NIH) budget uncertainties and the impact of government spending cuts have weighed on the research business, exacerbated by the U.S. government shutdown. Uncertainty surrounding academic funding is expected to sustain through the balance of 2013.
Moreover, Sigma-Aldrich, which generates roughly 67% of its sales from the overseas markets, is highly exposed to currency headwinds. Foreign exchange headwind on earnings is expected to be around 10 cents per share for 2013.
Other Stocks to Consider
Other companies in the specialty chemical space with a favorable Zacks Rank are Ferro Corp. (FOE - Snapshot Report), HB Fuller Co. (FUL - Snapshot Report) and Ecolab Inc. (ECL - Analyst Report). All of these stocks have a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UNITED THER… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%